Reading the tape
NASDAQ: IMRX
Immuneering Corporation
Healthcare · Biotechnology
Market Cap
$195.49M
52w High
$10.08
52w Low
$1.10
P/E
-4.23
Volume
788.68K
Outstanding Shares
36.30M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 330.8%FCF (TTM): 17.42%
What changed
The stock rose 330.8% over the last year. Free cash flow grew 17.42% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates.
CEOBenjamin J. Zeskind
SectorHealthcare
IndustryBiotechnology
Employees54
IPO dateJul 30, 2021
Valuation
Forward P/E—
EV/EBITDA-2.81
Enterprise value$164.78M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-25.64%▲82.61%vs FY2024
Analyst consensus
RatingBuy
Target price$12.00▲122.84%
7
Buy
4
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 4, 2026
Q2 FY26 · EPS est -$0.30 · Revenue est —
View